Strides Pharma Science today announced that its step‐down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. from the United  States  Food  &  Drug  Administration  (US  FDA). 

The  product  is  a  generic  version  of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc.

According  to  IQVIA  MAT  data,  the  US  market  for  Triamcinolone  Acetonide  Cream  USP,  0.025%, 0.1% and 0.5%. is approximately US$ 55 Mn. The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market. 

The  company  has  86  cumulative  ANDA  filings  with  USFDA  of  which  56  ANDAs  have  been approved including 12 approvals received in FY 19.